Sign in Subscribe
Nanotechnology

Lipid-Polymer Hybrid Nanoparticles Hold Promise in Breast Cancer Treatment

Strategic Insights

— 1 min read

A new report explores the potential of lipid-polymer hybrid nanoparticles (LPHNPs) as a next-generation drug delivery system for breast cancer therapy. Breast cancer remains one of the most prevalent and deadly cancers worldwide, affecting women, and LPHNPs have shown promise in delivering single drugs, drug combinations, and nucleic acids like siRNA and miRNA. The review delves into the unique structure, preparation methods, and applications of LPHNPs in cancer therapy, emphasizing their potential for personalized medicine.

Key Takeaways:

  • LPHNPs have shown promise in treating breast cancer by delivering single drugs, drug combinations, and nucleic acids like siRNA and miRNA.
  • The literature search identified 20 relevant studies published from 2009 to 2025, showcasing advancements in drug delivery systems and therapeutic approaches.
  • The review categorizes LPHNPs and discusses their unique structure, preparation methods, and applications in cancer therapy, emphasizing their potential for personalized medicine.
  • Continued research and collaboration between researchers, clinicians, and regulatory bodies are essential to realize the benefits of LPHNPs in personalized cancer therapy.
  • LPHNPs have the ability to overcome drug resistance and enhance therapeutic efficacy, making them a cutting-edge frontier in breast cancer treatment strategies.
  • The transformative potential of LPHNPs in revolutionizing breast cancer treatment is emphasized, provided that challenges in formulation, scalability, and long-term safety are addressed.

Statistics:

  • 20 relevant studies were published from 2009 to 2025.
  • 1 in 8 women will develop breast cancer in their lifetime.
  • LPHNPs have shown promise in delivering single drugs, drug combinations, and nucleic acids like siRNA and miRNA.
  • The literature search was performed using PubMed, Scopus, and Web of Science databases.
  • Stemming from a report, 21% of newly diagnosed breast cancer in Malaysia is related to genetic predisposition.

Sources:

  • Lipid-polymer hybrid nanoparticles: a cutting-edge frontier in breast cancer treatment strategies. Nanomedicine, 2025:1-24.
  • Taylor & Francis Ltd, 2-4 Park Square, Milton Park, Abingdon OR14 4RN, Oxon, England.
  • International Islamic University Malaysia, INHART, Kuala Lumpur, Selangor, Malaysia.
  • NewsRx LLC.
  • VerticalNews.

Read more